Syneos Health is a fully integrated biopharmaceutical solutions organization that supports clinical, medical affairs, and commercial functions for drug development and launch. The company was created in August 2017 through the merger of INC Research and inVentiv Health.
The global drug discovery services market is valued at $22.04 billion in 2025 and is forecast to reach $75.13 billion by 2034, growing at a 14.6% CAGR from 2026-2034, driven by rising industry demand and technological advancements.
Analysts project AI in clinical trials will represent an $8 billion business segment by 2030, generating up to $110 billion per year in value to pharma. Multiple companies unveiled AI-powered platforms at SCOPE 2026 in Orlando.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07556159 |
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice |
RECRUITING | |
| NCT07497503 |
A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants |
RECRUITING | PHASE1 |
| NCT07413367 |
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07222813 |
Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP) |
NOT_YET_RECRUITING | NA |
| NCT06872658 |
Study to Detect Dendritic Cell Recruitment in Human Retina |
NOT_YET_RECRUITING | |
| NCT06780254 |
A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Single- and Multiple-Ascending Doses of MH-001 in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT06699836 |
The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06435039 |
A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers |
TERMINATED | PHASE1 |
| NCT06347315 |
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI) |
RECRUITING | NA |
| NCT06256731 |
ETNA-MS Device Validation Study |
COMPLETED |
